Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galectin Therapeutics

1.32
-0.1000-7.04%
Post-market: 1.31-0.0100-0.76%19:11 EDT
Volume:157.03K
Turnover:211.16K
Market Cap:83.40M
PE:-1.74
High:1.41
Open:1.40
Low:1.28
Close:1.42
Loading ...

Galectin Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
04 Apr

Galectin Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
02 Apr

H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)

TIPRANKS
·
02 Apr

Press Release: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Dow Jones
·
31 Mar

Galectin Therapeutics FY 2024 GAAP EPS $(0.76) Misses $(0.73) Estimate, Cash Balance Of $15.1M

Benzinga
·
31 Mar

Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
25 Mar

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap up US$10m last week, benefiting both retail investors who own 54% as well as insiders

Simply Wall St.
·
14 Mar

While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership

Simply Wall St.
·
08 Mar

Galectin Therapeutics Updates Investors on Clinical Trials

TIPRANKS
·
05 Mar

BRIEF-Galectin Therapeutics Inc - Reports Significant Reduction In New Varices With Belapectin

Reuters
·
18 Feb

Galectin Therapeutics’ belapectin shows reduction in new varices

TIPRANKS
·
18 Feb

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

GlobeNewswire
·
18 Feb

Galectin Therapeutics Inc - Navigate Trial Shows 68.1% Reduction in New Varices With Belapectin

THOMSON REUTERS
·
18 Feb

Galectin Therapeutics Unveils Promising NAVIGATE Trial Results

TIPRANKS
·
24 Jan

Galectin Therapeutics Highlights Promising NAVIGATE Trial Results

TIPRANKS
·
13 Jan

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

GlobeNewswire
·
10 Jan

Galectin Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
28 Dec 2024

HC Wainwright Downgrades Galectin Therapeutics to Neutral From Buy

MT Newswires Live
·
28 Dec 2024

H.C. Wainwright downgrades Galectin Therapeutics after MASH trial fails

TIPRANKS
·
28 Dec 2024

Galectin Therapeutics (GALT) was downgraded to a Hold Rating at H.C. Wainwright

TIPRANKS
·
28 Dec 2024